TY - JOUR T1 - Once-daily triple therapy inhaler for COPD JF - Drug and Therapeutics Bulletin JO - Drug Ther Bull SP - 42 LP - 45 DO - 10.1136/dtb.2018.4.0611 VL - 56 IS - 4 A2 - , Y1 - 2018/04/01 UR - http://dtb.bmj.com/content/56/4/42.abstract N2 - â–¼Trelegy Ellipta (GSK) is a dry powder inhaler containing fluticasone furoate (inhaled corticosteroid [ICS]), vilanterol trifenatate (long-acting beta2 agonist [LABA]) and umeclidinium bromide (long-acting muscarinic antagonist [LAMA]).1 It is licensed for once-daily use as maintenance treatment for adults with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS and a LABA. Here, we consider the evidence for this combination product and discuss how it fits with current management strategies. ER -